The governments of the United States, the European Commission, Japan, Switzerland, Australia, New Zealand, South Korea, Canada, and Mexico are negotiating a trade agreement named the Anti-Counterfeiting Trade Agreement (ACTA). Despite the name, the agreement is designed to address not… Continue Reading
The USTR’s Special 301 Report has been issued every year beginning in 1989. The Executive Summary of the 2009 report says: The “Special 301” Report is an annual review of the global state of intellectual property rights (IPR) protection and… Continue Reading
More on Fabry here: https://keionline.org/fabry NIH rejects Fabrazyme March-In Petition December 7, 2010. Press release from Fabry patients: DHHS denies patient’s march-in request to end Genzyme’s rationing of treatment for Fabry Disease citing that FDA rules block manufactures from supplying… Continue Reading
You also can search for our most recent work on chimeric antigen receptor T-cell (CAR T) technologies using our tags here, or via our general search engine here. NIH CRADAs involving antigen receptor technologies. See this sheet. CAR patent litigation… Continue Reading
You also can search for our most recent work on clustered regularly interspaced short palindromic repeats (CRISPR) technologies using our tags here, or via our general search engine here. KEI Events regarding CRISPR 2019: Expert Workshop at Brocher Foundation- An… Continue Reading
(More on government funded inventions here: https://keionline.org/government-funded-inventions) On December 9, 2016, the U.S. Army announced its intent to grant an exclusive license to Sanofi on patents for a U.S. Army-developed Zika vaccine. KEI and various other non-profit groups have filed… Continue Reading
We have several pages related specifically to the U.S. Bayh-Dole Act here. KEI efforts to address pricing and other public interest issues in more than 30 different NIH licensing cases, involving both patents and data rights, are here: http://keionline.org/nih-licenses KEI… Continue Reading
Thiru Balasubramaniam is the Geneva Representative of Knowledge Ecology International. Mr. Balasubramaniam has represented KEI in various multilateral fora including the Marrakesh Diplomatic Conference to Conclude a Treaty to Facilitate Access to Published Works by Visually Impaired Persons and Persons… Continue Reading
Below are a few links to pages that show our work in specific fields (note: this list is currently under construction and will be continually updated): Innovation and access to medical technologies Cancer Drugs Coronavirus/COVID-19 Orphan/Rare diseases A standalone page… Continue Reading
On Wednesday, 24 January 2018, the World Health Organization’s (WHO) Executive Board is expected to discuss agenda item 3.6 on Addressing the global shortage of, and access to, medicines and vaccines. Non-state actors in official relations with the WHO are… Continue Reading